Reduction of baclofen-, but not sodium valproate-induced growth hormone release in type I diabetic men.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.

The effects of sodium valproate (a drug enhancing endogenous gamma aminobutyric acid (GABA)-ergic activity) and of the GABA analog baclofen (a GABA B receptor agonist) on serum GH levels was tested in 8 type I diabetic men and 8 normal controls.

Control tests with a placebo were performed on different occasions.

Who Took Part

The study group was 8 men.

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

The design is described as placebo-controlled.

Some men received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

What Was Measured

The effects of sodium valproate (a drug enhancing endogenous gamma aminobutyric acid (GABA)-ergic activity) and of the GABA analog baclofen (a GABA B receptor agonist) on serum GH levels was tested in 8 type I diabetic men and 8 normal controls.

Control tests with a placebo were performed on different occasions.

The subject headings attached to it are Baclofen, Diabetes Mellitus, Type 1, Growth Hormone, Receptors, GABA-A, Valproic Acid and gamma-Aminobutyric Acid.

What This Means in Plain Language

The paper is a placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 8 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1991 (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.